Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 9 · below the Ichimoku cloud · RSI 14 (oversold) · MACD below its signal · 5% above its 52-week low
| 3.54 | 52-week high | +660.71% |
| 1.63 | Previous month high | +249.69% |
| 1.24 | Previous week high | +166.84% |
| 1.22 | Previous month low | +162.53% |
| 0.5090 | R3 (classic) | +9.53% |
| 0.4930 | R2 (classic) | +6.09% |
| 0.4790 | R1 (classic) | +3.08% |
| 0.4770 | Previous day high | +2.65% |
| 0.4647 | Price now | |
| 0.4630 | Pivot | −0.37% |
| 0.4490 | S1 (classic) | −3.38% |
| 0.4470 | Previous day low | −3.81% |
| 0.4430 | Previous week low | −4.67% |
| 0.4430 | 52-week low | −4.67% |
| 0.4330 | S2 (classic) | −6.82% |
| 0.4190 | S3 (classic) | −9.83% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $4.9M | 0.01% | 2.77M | +7.1% | Q2 2026 |
| Maverick Capital · Lee Ainslie | $1.1M | 0.01% | 652.54K | — | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CRBU trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -11.3 | 34.8 | 0.0 | -1.1 | 25.5 | -25.4 | -17.0 | 5.5 | -17.5 | -63.4 | −70.8% | ||
| 2025 | -10.1 | -18.2 | -22.0 | -6.8 | 24.6 | 18.9 | 61.1 | -7.9 | 24.6 | 3.9 | -19.8 | -18.0 | −0.0% |
| 2024 | 7.0 | 29.0 | -35.0 | -29.4 | -20.7 | -43.1 | 41.5 | -6.9 | -9.3 | 0.0 | 11.7 | -27.4 | −72.3% |
| 2023 | 14.8 | -15.5 | -12.8 | -19.0 | 2.6 | -3.6 | 69.2 | -18.1 | -18.8 | -24.1 | 61.7 | -2.4 | −8.8% |
| 2022 | -28.9 | -7.0 | -8.0 | -19.4 | 12.6 | -34.8 | 49.5 | 21.6 | 6.9 | -7.7 | -4.4 | -32.5 | −58.4% |
| 2021 | 67.9 | -12.2 | -7.4 | -15.9 | -18.8 | −6.9% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Feb 24, 2026 | Kelly Timothy PChief Technology Officer | Sale at price 1.93 per share. | 6.2K | $12.02K |
| Feb 23, 2026 | Mcclung Barbara GOfficer | Sale at price 1.96 per share. | 6.9K | $13.60K |
| Feb 23, 2026 | Kelly Timothy PChief Technology Officer | Sale at price 1.96 per share. | 3.1K | $6.17K |
| Feb 23, 2026 | Khan Ruhi AhmadOfficer | Sale at price 1.96 per share. | 6.9K | $13.60K |
| Feb 23, 2026 | Albertson Tina M.Officer | Sale at price 1.96 per share. | 1.1K | $2.09K |
| Feb 19, 2026 | Mcclung Barbara GOfficer | Stock Award(Grant) at price 0.00 per share. | 45K | — |
| Feb 19, 2026 | Haurwitz Rachel E. Ph.D.Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 151.7K | — |
| Feb 19, 2026 | Kelly Timothy PChief Technology Officer | Stock Award(Grant) at price 0.00 per share. | 45K | — |
| Feb 19, 2026 | Ryali SriramChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 55K | — |
| Feb 19, 2026 | Khan Ruhi AhmadOfficer | Stock Award(Grant) at price 0.00 per share. | 45K | — |
| Feb 19, 2026 | Albertson Tina M.Officer | Stock Award(Grant) at price 0.00 per share. | 55K | — |
| Mar 13, 2025 | Haurwitz Rachel E. Ph.D.Chief Executive Officer | Purchase at price 1.02 per share. | 20K | $20.40K |
| Feb 20, 2025 | Mcclung Barbara GOfficer | Sale at price 1.35 per share. | 3.6K | $4.81K |
| Feb 20, 2025 | Kanner Steven B.Officer | Sale at price 1.35 per share. | 3.6K | $4.81K |
| Feb 20, 2025 | Khan Ruhi AhmadOfficer | Sale at price 1.35 per share. | 3.6K | $4.81K |
| Feb 19, 2025 | Mcclung Barbara GOfficer | Stock Award(Grant) at price 0.00 per share. | 37.5K | — |
| Feb 19, 2025 | Haurwitz Rachel E. Ph.D.Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 136.8K | — |
| Feb 19, 2025 | Kelly Timothy PChief Technology Officer | Stock Award(Grant) at price 0.00 per share. | 37.5K | — |
| Feb 19, 2025 | Kanner Steven B.Officer | Stock Award(Grant) at price 0.00 per share. | 37.5K | — |
| Feb 19, 2025 | Khan Ruhi AhmadOfficer | Stock Award(Grant) at price 0.00 per share. | 37.5K | — |
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Buy / hold / sell counts